NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA,
HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR
RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY
OF THE SECURITIES DESCRIBED HEREIN.  

Reference is made to the stock exchange announcement published by SoftOx
Solution AS (the "Company") earlier today, 2nd of September 2024, regarding the
final results of the rights issue (the "Rights Issue").  

The following primary insiders and close associates to primary insiders have
been allocated new shares in the Rights Issue: 

Bonica AS, a company owned by Ingrid Juven, the ICFO in the Company, has been
allocated 67 678 282 shares in the Company. As a result, Ingrid Juven together
with her fully owned company Bonica AS holds 85 178 282 shares in the Company. 

The other primary insiders referred to in the stock notice 26.08.2024 are
allocated shares in the Rights Issue according to the amount in the stock notice
of 26.08.2024.

For any questions please contact:  

Geir Almås, Chair of SoftOx Solutions AS  

Mail: ir@soft-ox.com  

Phone: Geir Almås: (+47) 977 59 071  

About SoftOx Solutions AS  

SoftOx Solutions AS (SoftOx) is a Medtech, and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes the holding
company SoftOx Solutions AS, the Malmö subsidiary Water Innovation AB, and
subsidiaries SoftOx Defense Solutions AS and SoftOx Disinfection AS. SoftOx is
developing a highly effective antimicrobial solution for biofilm, viral, and
antimicrobial-resistant infections. The patent-protected technology is based on
extensive research and development in partnership with leading Nordic research
institutes. 

For more information on SoftOx, visit www.soft-ox.com